baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Morgan Stanley Knock-Out REGN/ DE000MB8YLC8 /

2024-05-31 9:58:26 PM	Chg.+0.10	Bid10:00:33 PM	Ask10:00:33 PM	Underlying	Strike price	Expiration date	Option type
3.61EUR	+2.85%	- Bid Size: -	- Ask Size: -	Regeneron Pharmaceut...	588.692 USD	2078-12-31	Call

GlobeNewswire 05-31 Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD

GlobeNewswire 05-31 Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD

GlobeNewswire 05-31 Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...

GlobeNewswire 05-31 Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with typ...

GlobeNewswire 05-29 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach

GlobeNewswire 05-28 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...

GlobeNewswire 05-23 Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Com...

GlobeNewswire 05-22 Invivyd Elects Two New Independent Members to its Board of Directors

GlobeNewswire 05-21 Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update

GlobeNewswire 05-20 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...

GlobeNewswire 05-20 Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...

GlobeNewswire 05-20 Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...

GlobeNewswire 05-20 Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encou...

GlobeNewswire 05-17 More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International ...

GlobeNewswire 05-14 Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Sci...

GlobeNewswire 05-14 Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer

GlobeNewswire 05-13 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...

GlobeNewswire 05-10 Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire 05-09 Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company P...

GlobeNewswire 05-08 Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound G...

GlobeNewswire 05-07 Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference

GlobeNewswire 05-06 Regeneron Announces Investor Conference Presentations

GlobeNewswire 05-02 Regeneron Reports First Quarter 2024 Financial and Operating Results

GlobeNewswire 04-29 EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Mean...

GlobeNewswire 04-26 Medigene AG reports Financial Results and Business Update for Q1 2024

Morgan Stanley Knock-Out REGN/ DE000MB8YLC8 /

If you wish to receive reply to your feedback, please provide your email address.